Table 1.
Group comparison with treatment failure and success of infected orthopaedic implants after fracture (non-arthroplasty)
| Failure | Comparison | Remission | |
|---|---|---|---|
| n = 139 | n = 11 | p valuea | n = 128 |
| Female gender | 5 (45 %) | 46 (36 %) | |
| Age group ≤ 40 years | 5 (45 %) | 45 (35 %) | |
| Age group 41–62 years | 2 (18 %) | 40 (31 %) | |
| Age group > 63 years | 4 (36 %) | 43 (34 %) | |
| Immunosuppressionb | 2 (18 %) | 26 (20 %) | |
| Plate-related infection | 10 (91 %) | 0.010 | 65 (51 %) |
| Nail-related infection | 1 (9 %) | 23 (18 %) | |
| Screw, cerclage and wire | 0 (0 %) | 30 (23 %) | |
| Implant on lower extremity | 10 (91 %) | 101 (80 %) | |
| Tibial implant infection | 5 (45 %) | 64 (50 %) | |
| Implant on upper extremity | 1 (9 %) | 13 (10 %) | |
| Due to S. aureus | 4 (36 %) | 69 (54 %) | |
| Due to P aeruginosa | 2 (18 %) | 0.038 | 5 (4 %) |
| Second surgical look | 9 (82 %) | 105 (82 %) | |
| Implant retention (vs removal) | 3 (27 %) | 17 (13 %) | |
| Total antibiotic therapy < 6 weeks | 3 (27 %) | 75 (59 %) | |
| Total antibiotic therapy 6–9 weeks | 2 (18 %) | 8 (6 %) | |
| Total antibiotic therapy > 9 weeks | 6 (55 %) | 45 (35 %) | |
| Parenteral antibiotic therapy ≤ 4 days | 5 (45 %) | 57 (45 %) | |
| Parenteral antibiotic therapy > 4 days | 6 (55 %) | 71 (55 %) |
aOnly p values ≤0.05 (two-tailed) are displayed, χ2 or Fisher’s exact test
bDiabetes mellitus, immunosuppressive therapy, dialysis, Child’s class C cirrhosis, active cancer